The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.

Shuichi Hironaka,Ryo Sadachi,Tadayoshi Hashimoto,Nozomu Machida,Satoru Iwasa,Y. Yamada,Mitsuru Sasako,Narikazu Boku,Takaki Yoshikawa,Masanori Terashima

The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.

2021

Shuichi Hironaka
Ryo Sadachi
Tadayoshi Hashimoto
Nozomu Machida
Satoru Iwasa
Y. Yamada
Mitsuru Sasako
Narikazu Boku
Takaki Yoshikawa
Masanori Terashima

197Background: JCOG1013, a phase III study comparing CS therapy with DCS therapy for AGC, failed to demonstrate the superiority of DCS to CS in overall survival (OS) (Yamada Y, Lancet GH 2019). Bec...

Keywords:

Internal medicine
Oncology
Docetaxel
Correlation and dependence
Medicine
Cisplatin
overall survival
Renal function
in patient
exploratory analysis
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations